{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T11:34:54Z","timestamp":1789644894394,"version":"4.0.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,8]]},"DOI":"10.7759\/cureus.106661","type":"journal-article","created":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T16:15:22Z","timestamp":1775664922000},"source":"Crossref","is-referenced-by-count":1,"title":["The Price of Remission: Modeling the Total Financial Burden, Quality-of-Life Impairment, and Healthcare Dependence in Lupus Compared With Chimeric Antigen Receptor (CAR) T-cell Therapy"],"prefix":"10.7759","author":[{"given":"Kareena","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780350606","article-title":"Derivation of the SLEDAI. A disease activity index for lupus patients","volume":"35","author":"Bombardier C","year":"1992","unstructured":"Bombardier C, Gladman DD, Urowitz MB, et al.. Derivation of the SLEDAI. A disease activity index for lupus patients. Arthritis Rheum. 1992, 35:630-40. 10.1002\/art.1780350606","journal-title":"Arthritis Rheum"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2013.802241","article-title":"A longitudinal analysis of costs associated with change in disease activity in systemic lupus erythematosus","volume":"16","author":"Kan H","year":"2013","unstructured":"Kan H, Guerin A, Kaminsky MS, et al.. A longitudinal analysis of costs associated with change in disease activity in systemic lupus erythematosus. J Med Econ. 2013, 16:793-800. 10.3111\/13696998.2013.802241","journal-title":"J Med Econ"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2014.12.008","article-title":"Neurobehavioral consequences of small molecule-drug immunosuppression","volume":"96","author":"B\u00f6sche K","year":"2015","unstructured":"B\u00f6sche K, Weissenborn K, Christians U, Witzke O, Engler H, Schedlowski M, Hadamitzky M. Neurobehavioral consequences of small molecule-drug immunosuppression. Neuropharmacology. 2015, 96:83-93. 10.1016\/j.neuropharm.2014.12.008","journal-title":"Neuropharmacology"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2024-001291","article-title":"Impact of quality of life on overall work productivity impairment and activity impairment of patients with systemic lupus erythematosus: the PEONY study","volume":"12","author":"Tanaka Y","year":"2025","unstructured":"Tanaka Y, Miyazaki Y, Hirata S, et al.. Impact of quality of life on overall work productivity impairment and activity impairment of patients with systemic lupus erythematosus: the PEONY study. Lupus Sci Med. 2025, 12:10.1136\/lupus-2024-001291","journal-title":"Lupus Sci Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1177\/09612033221146093","article-title":"The cost of flares among patients with systemic lupus erythematosus with and without lupus nephritis in the United States","volume":"32","author":"Bell CF","year":"2023","unstructured":"Bell CF, Huang SP, Cyhaniuk A, Averell CM. The cost of flares among patients with systemic lupus erythematosus with and without lupus nephritis in the United States. Lupus. 2023, 32:301-9. 10.1177\/09612033221146093","journal-title":"Lupus"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.191187","article-title":"Healthcare utilization and costs of systemic lupus erythematosus by disease severity in the United States","volume":"48","author":"Murimi-Worstell IB","year":"2021","unstructured":"Murimi-Worstell IB, Lin DH, Kan H, et al.. Healthcare utilization and costs of systemic lupus erythematosus by disease severity in the United States. J Rheumatol. 2021, 48:385-93. 10.3899\/jrheum.191187","journal-title":"J Rheumatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen A","year":"2022","unstructured":"Mackensen A, M\u00fcller F, Mougiakakos D, et al.. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat Med. 2022, 28:2124-32. 10.1038\/s41591-022-02017-5","journal-title":"Nat Med"},{"key":"ref8","article-title":"CAR-T therapy in rheumatoid arthritis: a health systems analysis of cost and global equity","volume":"77","author":"Gandu AR","year":"2025","unstructured":"Gandu AR, Prathyusha K. CAR-T therapy in rheumatoid arthritis: a health systems analysis of cost and global equity. Arthritis Rheumatol. 2025, 77:","journal-title":"Arthritis Rheumatol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.2072","article-title":"Economic evaluation of chimeric antigen receptor T-cell therapy by site of care among patients with relapsed or refractory large B-cell lymphoma","volume":"3","author":"Lyman GH","year":"2020","unstructured":"Lyman GH, Nguyen A, Snyder S, Gitlin M, Chung KC. Economic evaluation of chimeric antigen receptor T-cell therapy by site of care among patients with relapsed or refractory large B-cell lymphoma. JAMA Netw Open. 2020, 3:10.1001\/jamanetworkopen.2020.2072","journal-title":"JAMA Netw Open"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2021-000640","article-title":"Real-world burden of systemic lupus erythematosus in the USA: a comparative cohort study from the Medical Expenditure Panel Survey (MEPS) 2016-2018","volume":"9","author":"Grabich S","year":"2022","unstructured":"Grabich S, Farrelly E, Ortmann R, Pollack M, Wu SS. Real-world burden of systemic lupus erythematosus in the USA: a comparative cohort study from the Medical Expenditure Panel Survey (MEPS) 2016-2018. Lupus Sci Med. 2022, 9:10.1136\/lupus-2021-000640","journal-title":"Lupus Sci Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2024.105827","article-title":"Economic burden of systemic lupus erythematosus and lupus nephritis in France: a nationwide population-based study using the French medico-administrative (SNDS) claims database","volume":"92","author":"Arnaud L","year":"2025","unstructured":"Arnaud L, Fabry-Vendrand C, Todea R, et al.. Economic burden of systemic lupus erythematosus and lupus nephritis in France: a nationwide population-based study using the French medico-administrative (SNDS) claims database. Joint Bone Spine. 2025, 92:10.1016\/j.jbspin.2024.105827","journal-title":"Joint Bone Spine"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-021-00368-y","article-title":"The economic burden of lupus nephritis: a systematic literature review","volume":"9","author":"Thompson JC","year":"2022","unstructured":"Thompson JC, Mahajan A, Scott DA, Gairy K. The economic burden of lupus nephritis: a systematic literature review. Rheumatol Ther. 2022, 9:25-47. 10.1007\/s40744-021-00368-y","journal-title":"Rheumatol Ther"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph20043522","article-title":"Annual direct cost and cost-drivers of systemic lupus erythematosus: a multi-center cross-sectional study from CSTAR Registry","volume":"20","author":"Wang H","year":"2023","unstructured":"Wang H, Li M, Zou K, et al.. Annual direct cost and cost-drivers of systemic lupus erythematosus: a multi-center cross-sectional study from CSTAR Registry. Int J Environ Res Public Health. 2023, 20:10.3390\/ijerph20043522","journal-title":"Int J Environ Res Public Health"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202443","article-title":"Annual direct medical cost of active systemic lupus erythematosus in five European countries","volume":"73","author":"Doria A","year":"2014","unstructured":"Doria A, Amoura Z, Cervera R, et al.. Annual direct medical cost of active systemic lupus erythematosus in five European countries. Ann Rheum Dis. 2014, 73:154-60. 10.1136\/annrheumdis-2012-202443","journal-title":"Ann Rheum Dis"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2020.1740236","article-title":"Treatment patterns and medical cost of systemic lupus erythematosus patients in Japan: a retrospective claims database study","volume":"23","author":"Miyazaki C","year":"2020","unstructured":"Miyazaki C, Sruamsiri R, Mahlich J, Jung W. Treatment patterns and medical cost of systemic lupus erythematosus patients in Japan: a retrospective claims database study. J Med Econ. 2020, 23:786-99. 10.1080\/13696998.2020.1740236","journal-title":"J Med Econ"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-023-00532-6","article-title":"Clinical and economic burden of systemic lupus erythematosus in the years preceding end-stage kidney disease diagnosis: a retrospective observational study","volume":"10","author":"Huang SP","year":"2023","unstructured":"Huang SP, Guisinger A, Averell C, Bell CF, Rubin B. Clinical and economic burden of systemic lupus erythematosus in the years preceding end-stage kidney disease diagnosis: a retrospective observational study. Rheumatol Ther. 2023, 10:551-62. 10.1007\/s40744-023-00532-6","journal-title":"Rheumatol Ther"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2021-000503","article-title":"Disease and economic burden increase with systemic lupus erythematosus severity 1 year before and after diagnosis: a real-world cohort study, United States, 2004-2015","volume":"8","author":"Jiang M","year":"2021","unstructured":"Jiang M, Near AM, Desta B, Wang X, Hammond ER. Disease and economic burden increase with systemic lupus erythematosus severity 1 year before and after diagnosis: a real-world cohort study, United States, 2004-2015. Lupus Sci Med. 2021, 8:10.1136\/lupus-2021-000503","journal-title":"Lupus Sci Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.13363","article-title":"Disease severity and economic burden in Japanese patients with systemic lupus erythematosus: a retrospective, observational study","volume":"21","author":"Tanaka Y","year":"2018","unstructured":"Tanaka Y, Mizukami A, Kobayashi A, Ito C, Matsuki T. Disease severity and economic burden in Japanese patients with systemic lupus erythematosus: a retrospective, observational study. Int J Rheum Dis. 2018, 21:1609-18. 10.1111\/1756-185X.13363","journal-title":"Int J Rheum Dis"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1177\/0961203316676641","article-title":"Hospitalization of patients with systemic lupus erythematosus is a major cause of direct and indirect healthcare costs","volume":"26","author":"Anandarajah AP","year":"2017","unstructured":"Anandarajah AP, Luc M, Ritchlin CT. Hospitalization of patients with systemic lupus erythematosus is a major cause of direct and indirect healthcare costs. Lupus. 2017, 26:756-61. 10.1177\/0961203316676641","journal-title":"Lupus"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1177\/09612033211073670","article-title":"An evaluation of costs associated with overall organ damage in patients with systemic lupus erythematosus in the United States","volume":"31","author":"Bell CF","year":"2022","unstructured":"Bell CF, Ajmera MR, Meyers J. An evaluation of costs associated with overall organ damage in patients with systemic lupus erythematosus in the United States. Lupus. 2022, 31:202-11. 10.1177\/09612033211073670","journal-title":"Lupus"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1007\/s40487-023-00228-5","article-title":"Component costs of CAR-T therapy in addition to treatment acquisition costs in patients with multiple myeloma","volume":"11","author":"Jagannath S","year":"2023","unstructured":"Jagannath S, Joseph N, Crivera C, et al.. Component costs of CAR-T therapy in addition to treatment acquisition costs in patients with multiple myeloma. Oncol Ther. 2023, 11:263-75. 10.1007\/s40487-023-00228-5","journal-title":"Oncol Ther"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1248867","article-title":"The future of affordable cancer immunotherapy","volume":"14","author":"Schaft N","year":"2023","unstructured":"Schaft N, D\u00f6rrie J, Schuler G, et al.. The future of affordable cancer immunotherapy. Front Immunol. 2023, 14:10.3389\/fimmu.2023.1248867","journal-title":"Front Immunol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2019.01.003","article-title":"Chimeric antigen receptor-T cell therapy manufacturing: modelling the effect of offshore production on aggregate cost of goods","volume":"21","author":"Harrison RP","year":"2019","unstructured":"Harrison RP, Zylberberg E, Ellison S, Levine BL. Chimeric antigen receptor-T cell therapy manufacturing: modelling the effect of offshore production on aggregate cost of goods. Cytotherapy. 2019, 21:224-33. 10.1016\/j.jcyt.2019.01.003","journal-title":"Cytotherapy"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33156","article-title":"Cost of decentralized CAR T-cell production in an academic nonprofit setting","volume":"147","author":"Ran T","year":"2020","unstructured":"Ran T, Eichm\u00fcller SB, Schmidt P, Schlander M. Cost of decentralized CAR T-cell production in an academic nonprofit setting. Int J Cancer. 2020, 147:3438-45. 10.1002\/ijc.33156","journal-title":"Int J Cancer"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-068683","article-title":"Association between depression and pain, functional disability, disease activity and health-related quality of life in patients with systemic lupus erythematosus: a meta-analysis","volume":"13","author":"Zhao Q","year":"2023","unstructured":"Zhao Q, Li X, Chen H, Wang L, Wu N, Ma J, Shen B. Association between depression and pain, functional disability, disease activity and health-related quality of life in patients with systemic lupus erythematosus: a meta-analysis. BMJ Open. 2023, 13:10.1136\/bmjopen-2022-068683","journal-title":"BMJ Open"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2019.06.017","article-title":"Prevalence and metric of depression and anxiety in systemic lupus erythematosus: a systematic review and meta-analysis","volume":"50","author":"Moustafa AT","year":"2020","unstructured":"Moustafa AT, Moazzami M, Engel L, et al.. Prevalence and metric of depression and anxiety in systemic lupus erythematosus: a systematic review and meta-analysis. Semin Arthritis Rheum. 2020, 50:84-94. 10.1016\/j.semarthrit.2019.06.017","journal-title":"Semin Arthritis Rheum"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.5114\/reum\/168396","article-title":"Depression, anxiety, and quality of life in patients with systemic lupus erythematosus","volume":"61","author":"Dehghan A","year":"2023","unstructured":"Dehghan A, Soltani H, Faezi ST, et al.. Depression, anxiety, and quality of life in patients with systemic lupus erythematosus. Reumatologia. 2023, 61:368-74. 10.5114\/reum\/168396","journal-title":"Reumatologia"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2022.28.12.1335","article-title":"Annual costs among patients with major depressive disorder and the impact of key clinical events","volume":"28","author":"Cutler AJ","year":"2022","unstructured":"Cutler AJ, Keyloun KR, Higa S, Park J, Bonafede M, Gillard P, Jain R. Annual costs among patients with major depressive disorder and the impact of key clinical events. J Manag Care Spec Pharm. 2022, 28:1335-43. 10.18553\/jmcp.2022.28.12.1335","journal-title":"J Manag Care Spec Pharm"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-019-00849-7","article-title":"Economic burden of anxiety disorders: a systematic review and meta-analysis","volume":"38","author":"Konnopka A","year":"2020","unstructured":"Konnopka A, K\u00f6nig H. Economic burden of anxiety disorders: a systematic review and meta-analysis. Pharmacoeconomics. 2020, 38:25-37. 10.1007\/s40273-019-00849-7","journal-title":"Pharmacoeconomics"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.37627","article-title":"The association between prolonged use of oral corticosteroids and mental disorders: do steroids have a role in developing mental disorders?","volume":"15","author":"Alturaymi MA","year":"2023","unstructured":"Alturaymi MA, Almadhi OF, Alageel YS, Dayel MB, Alsubayyil MS, Alkhateeb BF. The association between prolonged use of oral corticosteroids and mental disorders: do steroids have a role in developing mental disorders?. Cureus. 2023, 15:10.7759\/cureus.37627","journal-title":"Cureus"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/431383-the-price-of-remission-modeling-the-total-financial-burden-quality-of-life-impairment-and-healthcare-dependence-in-lupus-compared-with-chimeric-antigen-receptor-car-t-cell-therapy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T16:15:23Z","timestamp":1775664923000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/431383-the-price-of-remission-modeling-the-total-financial-burden-quality-of-life-impairment-and-healthcare-dependence-in-lupus-compared-with-chimeric-antigen-receptor-car-t-cell-therapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,8]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.106661","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4,8]]}}}